Current Issue : July-September Volume : 2025 Issue Number : 3 Articles : 1 Articles
The aim of the present study was to formulate, develop and evaluate Rasagiline mesylate nanoemulgel for transdermal drug delivery for enhanced permeation of the drug through the skin. Rasagiline mesylate belongs to class-III drug having low permeability. To overcome this low permeability, rasagiline mesylate was incorporated into nanoemulgel. Pseudo ternary-phase diagram was constructed to optimize the Smix ratio. Nanoemulsion was prepared by spontaneous emulsification method by using different ratios of oleic acid, tween 80 and span 80. Based on the desirability the optimized formulation was selected and incorporated into carbopol gel for transdermal drug delivery. The drug-excipients compatibility was confirmed by FTIR. The various parameters evaluated for nanoemulsions i.e., dilution test, conductivity, pH, viscosity, drug content and in-vitro drug release. Based on the results of these evaluations (F10) had shown best results and concluded as optimized formulation. The nanoemulsion formulations showed in-vitro drug release between 72.04±0.72 and 95.68±0.49 at the end of 7th hour and drug content from 72.23±0.39 to 81.64±0.55. The optimized formulation showed an average globule size of 190.1 nm and zeta potential was found to be -1.9 mV. The optimized formulation (F10) was incorporated into gel and evaluated for pH, spreadability, viscosity and in-vitro drug release. Gel formulation showed an in-vitro diffusion of 89.28±1.15% at the end of 7th hour. From this study, it was concluded that the formulated rasagiline mesylate nanoemulgel had given good drug release which indicates enhanced permeability thereby a probable increase in bioavailability....
Loading....